<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853901</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P56a/ 2020</org_study_id>
    <nct_id>NCT04853901</nct_id>
  </id_info>
  <brief_title>Remdesivir Efficacy In Management Of COVID-19 Patients</brief_title>
  <official_title>Remdesivir Efficacy In Management Of COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is open label randomized interventional phase 3 clinical trial. Patients with&#xD;
      confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain&#xD;
      Shams University and Assiut University ) assigned hospitals for isolation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is open label randomized interventional phase 3 clinical trial. Patients with&#xD;
      confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain&#xD;
      Shams University and Assiut University ) assigned hospitals for isolation.&#xD;
&#xD;
      The included patients receive. Intervention group: Remdesivir loading dose of 200 mg&#xD;
      intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone&#xD;
      1-2mg/kg for 5-7 days Control group: standard of care without Remdesivir&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of viral clearance</measure>
    <time_frame>14 days</time_frame>
    <description>Achievement of two successive negative COVID-19 PCR analysis tests 72 hours apart</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Remdesivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone 1-2mg/kg for 5-7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days + Methylprednisolone 1-2mg/kg for 5-7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days</description>
    <arm_group_label>Remdesivir</arm_group_label>
    <other_name>Veklury</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care_1</intervention_name>
    <description>Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days</description>
    <arm_group_label>Standard of care therapy</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care_2</intervention_name>
    <description>Methylprednisolone 1-2mg/kg for 5-7 days</description>
    <arm_group_label>Standard of care therapy</arm_group_label>
    <other_name>Steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult 18 -80 years old Must have laboratory confirmed COVID-19(A patient with laboratory&#xD;
        confirmation (Positive RT-PCR) of COVID-19 infection, irrespective of clinical signs and&#xD;
        symptoms according to Ain Shams University Hospitals Consensus Statement on Management of&#xD;
        Adult COVID-19 Patients.&#xD;
&#xD;
        Must have severe or immediately life-threatening COVID-19,&#xD;
&#xD;
          -  Severe disease is defined as:&#xD;
&#xD;
               -  Dyspnea,&#xD;
&#xD;
               -  Respiratory frequency ≥ 30/min,&#xD;
&#xD;
               -  Blood oxygen saturation ≤ 93%,&#xD;
&#xD;
               -  Partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt; 300,&#xD;
                  and/or lung infiltrates &gt; 50% within 24 to 48 hours&#xD;
&#xD;
          -  Life-threatening disease is defined as:&#xD;
&#xD;
               -  respiratory failure,&#xD;
&#xD;
               -  septic shock, and/or&#xD;
&#xD;
               -  multiple organ dysfunction or failure&#xD;
&#xD;
          -  Must provide informed consent by patient or his/her legal guardian or Professional&#xD;
             Legal Representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mild to moderately affected COVID 19 confirmed patients.&#xD;
&#xD;
          -  pregnancy, lactation.&#xD;
&#xD;
          -  known hepatic failure.&#xD;
&#xD;
          -  Patient who is not likely to comply to study procedures.&#xD;
&#xD;
          -  Creatine clearance &lt;30 ml/min.&#xD;
&#xD;
          -  Elevated transaminases &gt; 5 fold ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hany E Dabbous, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hany Dabbous</investigator_full_name>
    <investigator_title>Professor of Tropical Medicine Faculty of Medicine Ain Shams University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

